Agreements reached under this partnership
Business alliance- 1
From June 2026, the Company will independently commence promotional activities for the product.
- 2
After approval is granted for the addition of pulmonary MAC disease as an indication, the Company will receive supplies of the product from J&J and distribute it exclusively.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of entering into this agreement on the consolidated earnings forecast for the fiscal year ending March 2026 is immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | Janssen Pharmaceutical K.K. (Johnson & Johnson) |
| Alliance partner's business activities | Prescription pharmaceuticals business in Japan |
| Alliance partner's location | Chiyoda-ku, Tokyo |
| Type of alliance | Business alliance |
| Details of the alliance | From June 2026, the Company will independently commence promotional activities for the product., After approval is granted for the addition of pulmonary MAC disease as an indication, the Company will receive supplies of the product from J&J and distribute it exclusively. |
| Contract Date | 25 March 2026 |
| Alliance start date | June 2026 (scheduled) |
| Impact on Business Performance | The impact of entering into this agreement on the consolidated earnings forecast for the fiscal year ending March 2026 is immaterial. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The agreement is intended to expand the development pipeline through in-licensing, as set out in the medium-term management plan, and to acquire in-licensed products expected to contribute to earnings at an early stage. It will also enable the Company to contribute to patient treatment by adding to its product lineup under its strategy of concentrating resources in specific therapeutic areas.